Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  Pfizer Inc       

News SummaryMost relevantAll newsSector news 

Pfizer Inc. : Study Shows Positive Results for Pfizer's Lyrica Treatment for Fibromyalgia

share with twitter share with LinkedIn share with facebook
share via e-mail
11/19/2012 | 02:40pm CEST
   By Saabira Chaudhuri 

Pfizer Inc. (>> Pfizer Inc.) said results of a late-stage study of its pregabalin controlled-release formulation as a treatment for fibromyalgia were positive.

The drug company said top-line results of a Phase 3 study evaluating pregabalin controlled-release formulation, also known as Lyrica, in patients with fibromyalgia indicated that it had a statistically significant positive effect compared with a placebo with regards to time to loss of therapeutic response.

Pfizer described fibromyalgia as a common pain condition in the U.S. affecting more than five million Americans and characterized by chronic widespread pain and tenderness lasting for three or more months.

The most recent study is the second of three Phase 3 studies of the pregabalin controlled-release formulation, which Pfizer said will determine the potential use of pregabalin as a once-a-day therapy.

Last week, Pfizer had revealed that a Phase 3 study showed Lyrica as a potential epilepsy treatment didn't meet the primary endpoint for a change in seizure frequency. Monday, the drug company noted that the final study in post-herpetic neuralgia is ongoing.

"Collectively, the results of these controlled-release studies will allow us to better understand the potential of a once-a-day pregabalin treatment regimen," said Steven J. Romano, head of Pfizer's Global Primary Care Business Unit's Medicines Development Group. "Reducing the number of times patients need to take their medicine per day while maintaining the same efficacy and safety profile could potentially provide a greater convenience and the potential to enhance treatment adherence and outcomes."

Shares edged up 12 cents to $23.98 in recent premarket trading. The stock has risen 22% in the past year.

Write to Saabira Chaudhuri at saabira.chaudhuri@dowjones.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

Stocks mentioned in the article : Pfizer Inc.
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on PFIZER INC
03:11p PFIZER : Security National Trust Co buys $3,389,297 stake in Pfizer
10:11a ACTINIUM PHARMA : ceuticals Announces New Hires As Supply Chain Organization Exp..
10/26 PFIZER : Mayor proposes measures to combat heroin addiction
10/26 PFIZER : Lundbeck, MHRA, Merck, Pfizer to explore social media in the pharmaceut..
10/26 PFIZER : Ex-Oppenheimer & Co. worker pleads guilty to insider trading
10/24 ASTELLAS PHARMA : FDA Approves Supplemental New Drug Application for XTANDI (enz..
10/21 PFIZER : FDA Approves Supplemental New Drug Application for XTANDI® (enzalutamid..
10/21 CHEMOCENTRYX : Appoints Henry A. McKinnell, Jr. to Board of Directors
10/20 PFIZER : Patent Application Titled "Sildenafil Sublingual Spray Formulations" Pu..
More news
Sector news : Pharmaceuticals - NEC
08:35pDJApple Unveils New Macs, TV App
07:25p ASTRAZENECA : pauses two cancer drug trials' enrolment due to bleeding
07:15pDJBRISTOL MYERS SQUIBB : Makes Moves to Reassure Investors
07:13pDJBRISTOL MYERS SQUIBB : Makes Moves to Reassure Investors
10/26 GLAXOSMITHKLINE : British imports of cheap medicines dry up as pound falls
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
2015 Tracking Prem Watsa's Fairfax Financial Holdings Portfolio - Q2 2015 Update
2015 Antibiotics Stocks To Benefit From 21st Century Cures Act
2015 ISIS PHARMA STOCK DROPS ON GOOD NEWS : Re-Evaluating The Bull Case
2015 DOW DOGS : 14.63% More Returns From 5 Lowest Priced As Of August 6 Per indexArb
2015 Pfizer's GL-2045 an Orphan Drug for CIDP
Financials ($)
Sales 2016 52 991 M
EBIT 2016 19 366 M
Net income 2016 10 639 M
Debt 2016 28 244 M
Yield 2016 3,68%
P/E ratio 2016 17,89
P/E ratio 2017 14,61
EV / Sales 2016 4,24x
EV / Sales 2017 3,94x
Capitalization 196 527 M
More Financials
Duration : Period :
Pfizer Inc Technical Analysis Chart | 4-Traders
Full-screen chart
Income Statement Evolution
More Financials
Mean consensus OUTPERFORM
Number of Analysts 22
Average target price 38,7 $
Spread / Average Target 20%
Consensus details
EPS Revisions
More Estimates Revisions
Ian C. Read Chairman & Chief Executive Officer
Frank A. D'Amelio Chief Financial Officer & EVP-Business Operations
Freda C. Lewis-Hall Chief Medical Officer & Executive Vice President
Mikael Dolsten President-Worldwide Research & Development
Ole Isacson Chief Scientific Officer
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
PFIZER INC13.96%196 527
JOHNSON & JOHNSON11.53%313 422
ROCHE HOLDING LTD.-17.44%196 913
PFIZER INC.0.37%196 527
NOVARTIS AG-16.42%188 199
MERCK & CO., INC.15.24%168 318
More Results